Human immunodeficiency virus 2 p16 protease

processes HIV-1Pr53(gag) & analogous junction peptides in vitro; less than 60% amino acid identity to HIV-1 protease

Also Known As:

p16 protease, Human immunodeficiency virus 2; HIV-2 protease; HIV2 protease; p16 pol gene product, HIV-2; p16 pol gene product, Human immunodeficiency virus 2; p16 protease, HIV-2

Networked: 4 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Regad, Leslie: 2 articles (01/2021 - 10/2019)
2.	Laville, Pierre: 1 article (01/2021)
3.	Petitjean, Michel: 1 article (01/2021)
4.	Camproux, Anne-Claude: 1 article (10/2019)
5.	Descamps, Diane: 1 article (10/2019)
6.	Fartek, Sandrine: 1 article (10/2019)
7.	Triki, Dhoha: 1 article (10/2019)
8.	Visseaux, Benoit: 1 article (10/2019)
9.	Bacha, Usman M: 1 article (04/2008)
10.	Brower, Evan T: 1 article (04/2008)

Related Diseases

1.	Infections 01/25/2021 - "Here, we propose a structural analysis of 31 drug-resistant mutants of HIV-2 protease (PR2) that is an important target against HIV-2 infection. " 10/01/2019 - "The HIV-2 protease (PR2) is an important target for designing new drugs against the HIV-2 infection. " 04/01/2008 - "Current protease inhibitors have not been optimized for treatment of HIV-2 infection; therefore, it is important to assess the effectiveness of currently FDA-approved protease inhibitors against the HIV-2 protease, which shares only 50% sequence identity with the HIV-1 protease. "
2.	Acquired Immunodeficiency Syndrome (AIDS) 06/01/1993 - "In particular, it is useful for predicting the cleavability of an oligopeptide by either HIV-1 or HIV-2 protease, and hence offers a supplementary means for finding effective inhibitors of HIV protease as potential drugs against AIDS."

Related Drugs and Biologics

1.	HIV Protease
2.	Protease Inhibitors (Protease Inhibitor)
3.	Oligopeptides
4.	Human immunodeficiency virus 1 p16 protease